# Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer

> **NCT07127822** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University** · enrollment: 106 (estimated)

## Conditions studied

- Gastric / Gastroesophageal Junction Adenocarcinoma
- MSI-H Cancer

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab
- **DRUG:** First line chemotherapy plus PD-1/PD-L1 antibody

## Key facts

- **NCT ID:** NCT07127822
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2025-08-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07127822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07127822, "Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07127822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*